Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.

ClassNone selected
MechanismNone selected

No arms selected. Choose a drug, an arm, or a preset.

299 of 2118 arms with a reported figure. Choose arms to narrow the chart.

Adverse events

Participants, %

Source: Cited trial source. A count is not drawn as a percent unless the arm size is stored.

X axis: arm. Y axis: participants, %.

Semaglutide 7.2 mg
Semaglutide Placebo
Show as table
ArmAny adverse event, %Serious adverse event, %Discontinued for an adverse event, %Nausea, %Vomiting, %Diarrhea, %
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutide placebon/rn/rn/rn/rn/rn/r
Semaglutide 7.2 mgn/rn/r5.4%n/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/r1%n/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/rn/rn/r
Semaglutide 1.0 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutide placebo I/IIn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/rn/rn/r
Semaglutide 15 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutide placebo OWn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Semaglutide placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/rn/rn/r
Semaglutide Insuline glargine U100 (reduced) + semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Insuline glargine U100 (titrated)n/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/rn/rn/r
Semaglutide 7.2 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide 1.7 mgn/rn/rn/rn/rn/rn/r
Semaglutide 1.7 mgn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebo, in trialn/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebo (semaglutide)n/rn/rn/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/rn/rn/r
Semaglutide Semaglutide, on treatmentn/rn/rn/rn/rn/rn/r
Semaglutide Placebo, on treatmentn/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide 5 mgn/rn/rn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/rn/rn/r
Tirzepatide 15 mgn/rn/rn/rn/rn/rn/r
Tirzepatide 15 mgn/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatide (lead-in)n/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatide MTDn/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatiden/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatiden/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatide MTD_GPI1n/rn/rn/rn/rn/rn/r
Tirzepatide Placebo_GPI1n/rn/rn/rn/rn/rn/r
Tirzepatide Tirzepatide MTD_GPI2n/rn/rn/rn/rn/rn/r
Tirzepatide Placebo_GPI2n/rn/rn/rn/rn/rn/r
Tirzepatide 15 mgn/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/rn/rn/r
Tirzepatide 15 mgn/rn/rn/rn/rn/rn/r
Tirzepatide Placebon/rn/rn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/rn/rn/r
Orforglipron Placebon/rn/rn/rn/rn/rn/r
Orforglipron 6 mgn/rn/rn/rn/rn/rn/r
Orforglipron 12 mgn/rn/rn/rn/rn/rn/r
Orforglipron Placebo QDn/rn/rn/rn/rn/rn/r
Orforglipron 6 mgn/rn/rn/rn/rn/rn/r
Orforglipron 12 mgn/rn/rn/rn/rn/rn/r
Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Cagrilintide/semaglutide Placebo s.c.n/rn/rn/rn/rn/rn/r
Retatrutide 4 mgn/rn/rn/rn/rn/rn/r
Retatrutide 9 mgn/rn/rn/rn/rn/rn/r
Retatrutide 12 mgn/rn/rn/rn/rn/rn/r
Retatrutide Placebon/rn/rn/rn/rn/rn/r
Survodutide 3.6 mgn/rn/rn/rn/rn/rn/r
Survodutide 6.0 mgn/rn/rn/rn/rn/rn/r
Survodutide Placebon/rn/rn/rn/rn/rn/r
Survodutide 0.6 mgn/rn/rn/rn/rn/rn/r
Survodutide Placebo groupn/rn/rn/rn/rn/rn/r
Survodutide 2.4 mgn/rn/rn/rn/rn/rn/r
Survodutide 3.6 mgn/rn/rn/rn/rn/rn/r
Survodutide 4.8 mgn/rn/rn/rn/rn/rn/r
VK2735 2.5 mgn/rn/rn/rn/rn/rn/r
VK2735 15 mgn/rn/rn/rn/rn/rn/r
VK2735 Placebo 13 weeksn/rn/rn/rn/rn/rn/r
Eloralintide Placebon/rn/rn/rn/rn/rn/r
Eloralintide 1 mgn/rn/rn/rn/rn/rn/r
Eloralintide 3 mgn/rn/rn/rn/rn/rn/r
Eloralintide 6 mgn/rn/rn/rn/rn/rn/r
Eloralintide 9 mgn/rn/rn/rn/rn/rn/r
Berobenatide Placebon/rn/rn/rn/rn/rn/r
Dulaglutide Dulaglutide Armn/rn/rn/rn/rn/rn/r
Dulaglutide Placebo Armn/rn/rn/rn/rn/rn/r
Exenatide Group An/rn/rn/rn/rn/rn/r
Exenatide Group Bn/rn/rn/rn/rn/rn/r
Exenatide Exenatiden/rn/rn/rn/rn/rn/r
Exenatide Placebon/rn/rn/rn/rn/rn/r
Exenatide Exenatide once weekly (EQW )n/rn/rn/rn/rn/rn/r
Exenatide Dapagliflozin (DAPA)n/rn/rn/rn/rn/rn/r
Exenatide EQW plus DAPAn/rn/rn/rn/rn/rn/r
Exenatide Dapagliflozin plus Glucophage (MET ER)n/rn/rn/rn/rn/rn/r
Exenatide Phentermine /Topiramate (PHEN/ TPM) ERn/rn/rn/rn/rn/rn/r
Exenatide Exenatide once weekly extended-releasen/rn/rn/rn/rn/rn/r
Exenatide Matching placebon/rn/rn/rn/rn/rn/r
Exenatide Group An/rn/rn/rn/rn/rn/r
Exenatide Group Bn/rn/rn/rn/rn/rn/r
Liraglutide 3.0mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0mgn/rn/rn/rn/rn/rn/r
Liraglutide Liraglutide Placebo, no Pre-diabetesn/rn/rn/rn/rn/rn/r
Liraglutide Liraglutide Placebo, Pre-diabetesn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 1.8 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide Semaglutiden/rn/rn/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/rn/rn/r
Liraglutide Placebo (liraglutide)n/rn/rn/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebo, in trialn/rn/rn/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide Metformin XR plus liraglutiden/rn/rn/rn/rn/rn/r
Liraglutide Metformin XR plus placebon/rn/rn/rn/rn/rn/r
Liraglutide Liraglutide Pen Injector (Saxenda)n/rn/rn/rn/rn/rn/r
Liraglutide Placebo liraglutide pen injectorn/rn/rn/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/rn/rn/r
Liraglutide 0.05 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.1 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.2 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.3 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.4 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Placebo + Metforminn/rn/rn/rn/rn/rn/r
Liraglutide Liraglutide + Metforminn/rn/rn/rn/rn/rn/r
Liraglutide 100 mcgn/rn/rn/rn/rn/rn/r
Liraglutide 200 mcgn/rn/rn/rn/rn/rn/r
Liraglutide 300 mcgn/rn/rn/rn/rn/rn/r
Liraglutide 2.4 mgn/rn/rn/rn/rn/rn/r
Liraglutide 4.5 mgn/rn/rn/rn/rn/rn/r
Liraglutide 1.2 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.6 mgn/rn/rn/rn/rn/rn/r
Liraglutide 0.3 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/rn/rn/r
Liraglutide Orlistatn/rn/rn/rn/rn/rn/r
Lixisenatide Lixisenatiden/rn/rn/rn/rn/rn/r
Lixisenatide Sitagliptinn/rn/rn/rn/rn/rn/r
Mazdutide 3/6 Milligrams (mg) Mazdutiden/rn/rn/rn/rn/rn/r
Mazdutide 10 mgn/rn/rn/rn/rn/rn/r
Mazdutide 16 mgn/rn/rn/rn/rn/rn/r
Mazdutide Placebon/rn/rn/rn/rn/rn/r
Mazdutide 6 mgn/rn/rn/rn/rn/rn/r
Oral Semaglutide Oral semaglutiden/rn/rn/rn/rn/rn/r
Oral Semaglutide Oral semaglutide placebon/rn/rn/rn/rn/rn/r
Oral Semaglutide 25 mgn/rn/rn/rn/rn/rn/r
Oral Semaglutide Oral semaglutide placebon/rn/rn/rn/rn/rn/r
Oral Semaglutide 50 mgn/rn/rn/rn/rn/rn/r
Oral Semaglutide oral semaglutide placebo once dailyn/rn/rn/rn/rn/rn/r
TERN-601 250 mgn/rn/rn/rn/rn/rn/r
TERN-601 500 mgn/rn/rn/rn/rn/rn/r
TERN-601 750 mgn/rn/rn/rn/rn/rn/r
TERN-601 Matching Placebon/rn/rn/rn/rn/rn/r
CT-868 CT-868 Placebon/rn/rn/rn/rn/rn/r
CT-868 1.8 mgn/rn/rn/rn/rn/rn/r
CT-868 4.1 mgn/rn/rn/rn/rn/rn/r
CT-868 6.6 mgn/rn/rn/rn/rn/rn/r
HM15211 HM15211n/rn/rn/rn/rn/rn/r
HM15211 Placebon/rn/rn/rn/rn/rn/r
Pramlintide Placebo-P + Placebo-Mn/rn/rn/rn/rn/rn/r
Pramlintide 360 mcgn/rn/rn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/rn/rn/r
Pramlintide 2.5 mgn/rn/rn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/rn/rn/r
Pramlintide 1.25 mgn/rn/rn/rn/rn/rn/r
Pramlintide 2.5 mgn/rn/rn/rn/rn/rn/r
Pramlintide 5.0 mgn/rn/rn/rn/rn/rn/r
Pramlintide 1n/rn/rn/rn/rn/rn/r
Pramlintide 2n/rn/rn/rn/rn/rn/r
Pramlintide 3n/rn/rn/rn/rn/rn/r
Pramlintide Placebon/rn/rn/rn/rn/rn/r
Pramlintide Pramlintide + Metreleptinn/rn/rn/rn/rn/rn/r
Pramlintide Pramlintide Acetate and Placebon/rn/rn/rn/rn/rn/r
Pramlintide Lead-In Periodn/rn/rn/rn/rn/rn/r
Bimagrumab 30 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 30 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 30 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 1.0 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 2.4 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 1.0 mgn/rn/rn/rn/rn/rn/r
Bimagrumab 2.4 mgn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB16n/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB32n/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB32n/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB32n/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB32n/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion BWL + NB medicationn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion BWL + Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medicationn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion BWL + Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion NB medicationn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone+Bupropion Medicationn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Naltrexone/Bupropionn/rn/rn/rn/rn/rn/r
Naltrexone And Bupropion Placebon/rn/rn/rn/rn/rn/r
Orlistat Intensive Lifestyle Mod. Interventionn/rn/rn/rn/rn/rn/r
Orlistat Standard Lifestyle Interventionn/rn/rn/rn/rn/rn/r
Orlistat Placebon/rn/rn/rn/rn/rn/r
Orlistat Orlistatn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate VI-0521 Lown/rn/rn/rn/rn/rn/r
Phentermine And Topiramate VI-0521 Topn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Placebon/rn/rn/rn/rn/rn/r
Phentermine And Topiramate VI-0521 Topn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate VI-0521 Midn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate TPM 46n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate TPM 92n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate PHEN 7.5n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate PHEN 15n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Placebon/rn/rn/rn/rn/rn/r
Phentermine And Topiramate LSMT 12n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate LSMT 24n/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Phentermine & Topiramaten/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Placebo Drugsn/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Semaglutiden/rn/rn/rn/rn/rn/r
Phentermine And Topiramate Other anti-obesity medicationn/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide (Double-Blind)n/rn/rn/rn/rn/rn/r
Setmelanotide Placebo (Double-Blind)n/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide (Open-label)n/rn/rn/rn/rn/rn/r
Setmelanotide Pivotal Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide 2 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 2.5 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 3 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 20 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 25 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 3 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 30 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 20 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 25 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 30 mgn/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide: PPL Groupn/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotide: BBS Groupn/rn/rn/rn/rn/rn/r
Setmelanotide 16p11.2 Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide AS Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide BBS Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide MC4R Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide SH2B1 Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide SMS Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide SRC1 Cohortn/rn/rn/rn/rn/rn/r
Setmelanotide Stage 1: Setmelanotide (Open-Label)n/rn/rn/rn/rn/rn/r
Setmelanotide Stage 2: Setmelanotide (Double-Blind)n/rn/rn/rn/rn/rn/r
Setmelanotide Stage 2: Placebo (Double-Blind)n/rn/rn/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/rn/rn/r
Setmelanotide Setmelanotiden/rn/rn/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/rn/rn/r
Setmelanotide 0.5 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 1.5 mgn/rn/rn/rn/rn/rn/r
Setmelanotide 2.5 mgn/rn/rn/rn/rn/rn/r
Setmelanotide Placebon/rn/rn/rn/rn/rn/r
Sibutramine Sibutraminen/rn/rn/rn/rn/rn/r
Sibutramine Placebon/rn/rn/rn/rn/rn/r
Tesofensine placebo armn/rn/rn/rn/rn/rn/r

Not shown

  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo (semaglutide): no arm n for percent
  • Semaglutide 1.0 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide placebo I/II: no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Placebo, in trial: no arm n for percent
  • Semaglutide 15 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide placebo OW: no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Semaglutide placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Placebo, in trial: no arm n for percent
  • Semaglutide Insuline glargine U100 (reduced) + semaglutide: no arm n for percent
  • Semaglutide Insuline glargine U100 (titrated): no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo (semaglutide): no arm n for percent
  • Semaglutide 7.2 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide 1.7 mg: no arm n for percent
  • Semaglutide 1.7 mg: no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo (semaglutide): no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Placebo, in trial: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo (semaglutide): no arm n for percent
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide Semaglutide, on treatment: no arm n for percent
  • Semaglutide Placebo, on treatment: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide 5 mg: no arm n for percent
  • Tirzepatide 10 mg: no arm n for percent
  • Tirzepatide 15 mg: no arm n for percent
  • Tirzepatide 15 mg: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide 10 mg: no arm n for percent
  • Tirzepatide Tirzepatide (lead-in): no arm n for percent
  • Tirzepatide Tirzepatide MTD: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide Tirzepatide: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide Tirzepatide: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide Tirzepatide MTD_GPI1: no arm n for percent
  • Tirzepatide Placebo_GPI1: no arm n for percent
  • Tirzepatide Tirzepatide MTD_GPI2: no arm n for percent
  • Tirzepatide Placebo_GPI2: no arm n for percent
  • Tirzepatide 15 mg: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide 10 mg: no arm n for percent
  • Tirzepatide 15 mg: no arm n for percent
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide 10 mg: no arm n for percent
  • Orforglipron Placebo: no arm n for percent
  • Orforglipron 6 mg: no arm n for percent
  • Orforglipron 12 mg: no arm n for percent
  • Orforglipron Placebo QD: no arm n for percent
  • Orforglipron 6 mg: no arm n for percent
  • Orforglipron 12 mg: no arm n for percent
  • Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: no arm n for percent
  • Cagrilintide/semaglutide Placebo s.c.: no arm n for percent
  • Retatrutide 4 mg: no arm n for percent
  • Retatrutide 9 mg: no arm n for percent
  • Retatrutide 12 mg: no arm n for percent
  • Retatrutide Placebo: no arm n for percent
  • Survodutide 3.6 mg: no arm n for percent
  • Survodutide 6.0 mg: no arm n for percent
  • Survodutide Placebo: no arm n for percent
  • Survodutide 0.6 mg: no arm n for percent
  • Survodutide Placebo group: no arm n for percent
  • Survodutide 2.4 mg: no arm n for percent
  • Survodutide 3.6 mg: no arm n for percent
  • Survodutide 4.8 mg: no arm n for percent
  • VK2735 2.5 mg: no arm n for percent
  • VK2735 15 mg: no arm n for percent
  • VK2735 Placebo 13 weeks: no arm n for percent
  • Eloralintide Placebo: no arm n for percent
  • Eloralintide 1 mg: no arm n for percent
  • Eloralintide 3 mg: no arm n for percent
  • Eloralintide 6 mg: no arm n for percent
  • Eloralintide 9 mg: no arm n for percent
  • Berobenatide Placebo: no arm n for percent
  • Dulaglutide Dulaglutide Arm: no arm n for percent
  • Dulaglutide Placebo Arm: no arm n for percent
  • Exenatide Group A: no arm n for percent
  • Exenatide Group B: no arm n for percent
  • Exenatide Exenatide: no arm n for percent
  • Exenatide Placebo: no arm n for percent
  • Exenatide Exenatide once weekly (EQW ): no arm n for percent
  • Exenatide Dapagliflozin (DAPA): no arm n for percent
  • Exenatide EQW plus DAPA: no arm n for percent
  • Exenatide Dapagliflozin plus Glucophage (MET ER): no arm n for percent
  • Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: no arm n for percent
  • Exenatide Exenatide once weekly extended-release: no arm n for percent
  • Exenatide Matching placebo: no arm n for percent
  • Exenatide Group A: no arm n for percent
  • Exenatide Group B: no arm n for percent
  • Liraglutide 3.0mg: no arm n for percent
  • Liraglutide 3.0mg: no arm n for percent
  • Liraglutide Liraglutide Placebo, no Pre-diabetes: no arm n for percent
  • Liraglutide Liraglutide Placebo, Pre-diabetes: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 1.8 mg: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide Semaglutide: no arm n for percent
  • Liraglutide Liraglutide: no arm n for percent
  • Liraglutide Placebo (liraglutide): no arm n for percent
  • Liraglutide Liraglutide: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Placebo, in trial: no arm n for percent
  • Liraglutide Liraglutide: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide Metformin XR plus liraglutide: no arm n for percent
  • Liraglutide Metformin XR plus placebo: no arm n for percent
  • Liraglutide Liraglutide Pen Injector (Saxenda): no arm n for percent
  • Liraglutide Placebo liraglutide pen injector: no arm n for percent
  • Liraglutide Liraglutide: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 0.05 mg: no arm n for percent
  • Liraglutide 0.1 mg: no arm n for percent
  • Liraglutide 0.2 mg: no arm n for percent
  • Liraglutide 0.3 mg: no arm n for percent
  • Liraglutide 0.4 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Placebo + Metformin: no arm n for percent
  • Liraglutide Liraglutide + Metformin: no arm n for percent
  • Liraglutide 100 mcg: no arm n for percent
  • Liraglutide 200 mcg: no arm n for percent
  • Liraglutide 300 mcg: no arm n for percent
  • Liraglutide 2.4 mg: no arm n for percent
  • Liraglutide 4.5 mg: no arm n for percent
  • Liraglutide 1.2 mg: no arm n for percent
  • Liraglutide 0.6 mg: no arm n for percent
  • Liraglutide 0.3 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide Orlistat: no arm n for percent
  • Lixisenatide Lixisenatide: no arm n for percent
  • Lixisenatide Sitagliptin: no arm n for percent
  • Mazdutide 3/6 Milligrams (mg) Mazdutide: no arm n for percent
  • Mazdutide 10 mg: no arm n for percent
  • Mazdutide 16 mg: no arm n for percent
  • Mazdutide Placebo: no arm n for percent
  • Mazdutide 6 mg: no arm n for percent
  • Oral Semaglutide Oral semaglutide: no arm n for percent
  • Oral Semaglutide Oral semaglutide placebo: no arm n for percent
  • Oral Semaglutide 25 mg: no arm n for percent
  • Oral Semaglutide Oral semaglutide placebo: no arm n for percent
  • Oral Semaglutide 50 mg: no arm n for percent
  • Oral Semaglutide oral semaglutide placebo once daily: no arm n for percent
  • TERN-601 250 mg: no arm n for percent
  • TERN-601 500 mg: no arm n for percent
  • TERN-601 750 mg: no arm n for percent
  • TERN-601 Matching Placebo: no arm n for percent
  • CT-868 CT-868 Placebo: no arm n for percent
  • CT-868 1.8 mg: no arm n for percent
  • CT-868 4.1 mg: no arm n for percent
  • CT-868 6.6 mg: no arm n for percent
  • HM15211 HM15211: no arm n for percent
  • HM15211 Placebo: no arm n for percent
  • Pramlintide Placebo-P + Placebo-M: no arm n for percent
  • Pramlintide 360 mcg: no arm n for percent
  • Pramlintide 5.0 mg: no arm n for percent
  • Pramlintide 2.5 mg: no arm n for percent
  • Pramlintide 5.0 mg: no arm n for percent
  • Pramlintide 1.25 mg: no arm n for percent
  • Pramlintide 2.5 mg: no arm n for percent
  • Pramlintide 5.0 mg: no arm n for percent
  • Pramlintide 1: no arm n for percent
  • Pramlintide 2: no arm n for percent
  • Pramlintide 3: no arm n for percent
  • Pramlintide Placebo: no arm n for percent
  • Pramlintide Pramlintide + Metreleptin: no arm n for percent
  • Pramlintide Pramlintide Acetate and Placebo: no arm n for percent
  • Pramlintide Lead-In Period: no arm n for percent
  • Bimagrumab 30 mg: no arm n for percent
  • Bimagrumab 30 mg: no arm n for percent
  • Bimagrumab 30 mg: no arm n for percent
  • Bimagrumab 1.0 mg: no arm n for percent
  • Bimagrumab 2.4 mg: no arm n for percent
  • Bimagrumab 1.0 mg: no arm n for percent
  • Bimagrumab 2.4 mg: no arm n for percent
  • Naltrexone And Bupropion NB16: no arm n for percent
  • Naltrexone And Bupropion NB32: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion NB32: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion NB32: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion NB32: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion BWL + NB medication: no arm n for percent
  • Naltrexone And Bupropion BWL + Placebo: no arm n for percent
  • Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: no arm n for percent
  • Naltrexone And Bupropion BWL + Placebo: no arm n for percent
  • Naltrexone And Bupropion NB medication: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion Naltrexone+Bupropion Medication: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Naltrexone And Bupropion Naltrexone/Bupropion: no arm n for percent
  • Naltrexone And Bupropion Placebo: no arm n for percent
  • Orlistat Intensive Lifestyle Mod. Intervention: no arm n for percent
  • Orlistat Standard Lifestyle Intervention: no arm n for percent
  • Orlistat Placebo: no arm n for percent
  • Orlistat Orlistat: no arm n for percent
  • Phentermine And Topiramate VI-0521 Low: no arm n for percent
  • Phentermine And Topiramate VI-0521 Top: no arm n for percent
  • Phentermine And Topiramate Placebo: no arm n for percent
  • Phentermine And Topiramate VI-0521 Top: no arm n for percent
  • Phentermine And Topiramate VI-0521 Mid: no arm n for percent
  • Phentermine And Topiramate TPM 46: no arm n for percent
  • Phentermine And Topiramate TPM 92: no arm n for percent
  • Phentermine And Topiramate PHEN 7.5: no arm n for percent
  • Phentermine And Topiramate PHEN 15: no arm n for percent
  • Phentermine And Topiramate Placebo: no arm n for percent
  • Phentermine And Topiramate LSMT 12: no arm n for percent
  • Phentermine And Topiramate LSMT 24: no arm n for percent
  • Phentermine And Topiramate Phentermine & Topiramate: no arm n for percent
  • Phentermine And Topiramate Placebo Drugs: no arm n for percent
  • Phentermine And Topiramate Semaglutide: no arm n for percent
  • Phentermine And Topiramate Other anti-obesity medication: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Placebo: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Setmelanotide (Double-Blind): no arm n for percent
  • Setmelanotide Placebo (Double-Blind): no arm n for percent
  • Setmelanotide Setmelanotide (Open-label): no arm n for percent
  • Setmelanotide Pivotal Cohort: no arm n for percent
  • Setmelanotide 2 mg: no arm n for percent
  • Setmelanotide 2.5 mg: no arm n for percent
  • Setmelanotide 3 mg: no arm n for percent
  • Setmelanotide 20 mg: no arm n for percent
  • Setmelanotide 25 mg: no arm n for percent
  • Setmelanotide 3 mg: no arm n for percent
  • Setmelanotide 30 mg: no arm n for percent
  • Setmelanotide 20 mg: no arm n for percent
  • Setmelanotide 25 mg: no arm n for percent
  • Setmelanotide 30 mg: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Setmelanotide: PPL Group: no arm n for percent
  • Setmelanotide Setmelanotide: BBS Group: no arm n for percent
  • Setmelanotide 16p11.2 Cohort: no arm n for percent
  • Setmelanotide AS Cohort: no arm n for percent
  • Setmelanotide BBS Cohort: no arm n for percent
  • Setmelanotide MC4R Cohort: no arm n for percent
  • Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: no arm n for percent
  • Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: no arm n for percent
  • Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: no arm n for percent
  • Setmelanotide SH2B1 Cohort: no arm n for percent
  • Setmelanotide SMS Cohort: no arm n for percent
  • Setmelanotide SRC1 Cohort: no arm n for percent
  • Setmelanotide Stage 1: Setmelanotide (Open-Label): no arm n for percent
  • Setmelanotide Stage 2: Setmelanotide (Double-Blind): no arm n for percent
  • Setmelanotide Stage 2: Placebo (Double-Blind): no arm n for percent
  • Setmelanotide Placebo: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Placebo: no arm n for percent
  • Setmelanotide 0.5 mg: no arm n for percent
  • Setmelanotide 1.5 mg: no arm n for percent
  • Setmelanotide 2.5 mg: no arm n for percent
  • Setmelanotide Placebo: no arm n for percent
  • Sibutramine Sibutramine: no arm n for percent
  • Sibutramine Placebo: no arm n for percent
  • Tesofensine placebo arm: no arm n for percent
ArmNauseaVomitingDiarrheaDiscontinuation
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Semaglutide placebon/rn/rn/rn/r
Semaglutide 7.2 mgn/rn/rn/r5.4%
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/r1%
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)337 participants87 participants353 participantsn/r
Semaglutide 1.0 mg128 participants54 participants88 participantsn/r
Semaglutide 2.4 mg135 participants86 participants86 participantsn/r
Semaglutide Semaglutide placebo I/II37 participants11 participants48 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebo, in trial13 participants8 participants19 participantsn/r
Semaglutide 15 mg163 participants56 participants88 participantsn/r
Semaglutide 2.4 mg167 participants80 participants88 participantsn/r
Semaglutide 2.4 mg55 participants26 participants42 participantsn/r
Semaglutide Semaglutide placebo OW18 participants7 participants20 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Semaglutide placebon/rn/rn/rn/r
Semaglutide 2.4 mg237 participants111 participants147 participantsn/r
Semaglutide Placebo, in trial45 participants22 participants45 participantsn/r
Semaglutide Insuline glargine U100 (reduced) + semaglutiden/rn/rn/rn/r
Semaglutide Insuline glargine U100 (titrated)n/rn/rn/rn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)7 participants3 participants10 participantsn/r
Semaglutide 7.2 mg89 participants51 participants56 participantsn/r
Semaglutide 2.4 mg29 participants14 participants21 participantsn/r
Semaglutide Placebo12 participants3 participants9 participantsn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide 2.4 mg59 participants21 participants21 participantsn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide 2.4 mg35 participants17 participants32 participantsn/r
Semaglutide 1.7 mgn/rn/rn/rn/r
Semaglutide 1.7 mg18 participants10 participants22 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)9 participants0 participants13 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide 2.4 mg81 participants46 participants53 participantsn/r
Semaglutide Placebo, in trial33 participants7 participants36 participantsn/r
Semaglutide Placebo2 participants0 participants6 participantsn/r
Semaglutide 2.4 mg29 participants16 participants30 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo (semaglutide)3 participants1 participants7 participantsn/r
Semaglutide Semaglutiden/rn/rn/rn/r
Semaglutide Placebo12 participants7 participants13 participantsn/r
Semaglutide 2.4 mgn/rn/rn/rn/r
Semaglutide Placebon/rn/rn/rn/r
Semaglutide Semaglutide, on treatmentn/rn/rn/rn/r
Semaglutide Placebo, on treatment7 participants2 participants3 participantsn/r
Tirzepatide Placebon/rn/rn/rn/r
Tirzepatide 5 mgn/rn/rn/rn/r
Tirzepatide 10 mgn/rn/rn/rn/r
Tirzepatide 15 mgn/rn/rn/rn/r
Tirzepatide 15 mg68 participants40 participants66 participantsn/r
Tirzepatide Placebo20 participants10 participants28 participantsn/r
Tirzepatide 10 mg63 participants34 participants62 participantsn/r
Tirzepatide Tirzepatide (lead-in)278 participants128 participants165 participantsn/r
Tirzepatide Tirzepatide MTD27 participants18 participants36 participantsn/r
Tirzepatide Placebo9 participants4 participants16 participantsn/r
Tirzepatide Tirzepatide62 participants38 participants65 participantsn/r
Tirzepatide Placebo23 participants7 participants23 participantsn/r
Tirzepatide Tirzepatide114 participants52 participants89 participantsn/r
Tirzepatide Placebo41 participants4 participants27 participantsn/r
Tirzepatide Tirzepatide MTD_GPI129 participants20 participants30 participantsn/r
Tirzepatide Placebo_GPI112 participants5 participants15 participantsn/r
Tirzepatide Tirzepatide MTD_GPI226 participants11 participants26 participantsn/r
Tirzepatide Placebo_GPI26 participants1 participants10 participantsn/r
Tirzepatide 15 mg18 participants9 participants7 participantsn/r
Tirzepatide Placebo3 participants3 participants3 participantsn/r
Tirzepatide 10 mg10 participants5 participants9 participantsn/r
Tirzepatide 15 mg23 participants14 participants29 participantsn/r
Tirzepatide Placebo4 participants3 participants6 participantsn/r
Tirzepatide 10 mg21 participants8 participants28 participantsn/r
Orforglipron Placebo53 participants24 participants94 participantsn/r
Orforglipron 6 mg66 participants42 participants70 participantsn/r
Orforglipron 12 mg103 participants67 participants82 participantsn/r
Orforglipron Placebo QD0 participants0 participants2 participantsn/r
Orforglipron 6 mg8 participants4 participants9 participantsn/r
Orforglipron 12 mg9 participants5 participants4 participantsn/r
Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mgn/rn/rn/rn/r
Cagrilintide/semaglutide Placebo s.c.n/rn/rn/rn/r
Retatrutide 4 mgn/rn/rn/rn/r
Retatrutide 9 mgn/rn/rn/rn/r
Retatrutide 12 mgn/rn/rn/rn/r
Retatrutide Placebon/rn/rn/rn/r
Survodutide 3.6 mgn/rn/rn/rn/r
Survodutide 6.0 mgn/rn/rn/rn/r
Survodutide Placebon/rn/rn/rn/r
Survodutide 0.6 mg36 participants13 participants22 participantsn/r
Survodutide Placebo group15 participants4 participants8 participantsn/r
Survodutide 2.4 mg60 participants28 participants21 participantsn/r
Survodutide 3.6 mg45 participants28 participants17 participantsn/r
Survodutide 4.8 mg32 participants13 participants9 participantsn/r
VK2735 2.5 mgn/rn/rn/rn/r
VK2735 15 mgn/rn/rn/rn/r
VK2735 Placebo 13 weeksn/rn/rn/rn/r
Eloralintide Placebon/rn/rn/rn/r
Eloralintide 1 mgn/rn/rn/rn/r
Eloralintide 3 mgn/rn/rn/rn/r
Eloralintide 6 mgn/rn/rn/rn/r
Eloralintide 9 mgn/rn/rn/rn/r
Berobenatide Placebo13 participants6 participants5 participantsn/r
Dulaglutide Dulaglutide Arm2 participantsn/rn/rn/r
Dulaglutide Placebo Arm1 participantsn/rn/rn/r
Exenatide Group A43 participants21 participants18 participantsn/r
Exenatide Group B19 participants9 participants21 participantsn/r
Exenatide Exenatide24 participants11 participants16 participantsn/r
Exenatide Placebo19 participants8 participants16 participantsn/r
Exenatide Exenatide once weekly (EQW )n/rn/rn/rn/r
Exenatide Dapagliflozin (DAPA)n/rn/rn/rn/r
Exenatide EQW plus DAPAn/rn/rn/rn/r
Exenatide Dapagliflozin plus Glucophage (MET ER)n/rn/rn/rn/r
Exenatide Phentermine /Topiramate (PHEN/ TPM) ERn/rn/rn/rn/r
Exenatide Exenatide once weekly extended-release6 participants4 participants7 participantsn/r
Exenatide Matching placebo3 participants4 participants3 participantsn/r
Exenatide Group A18 participants6 participants10 participantsn/r
Exenatide Group B3 participants1 participants2 participantsn/r
Liraglutide 3.0mgn/rn/rn/rn/r
Liraglutide 3.0mgn/rn/rn/rn/r
Liraglutide Liraglutide Placebo, no Pre-diabetes78 participants25 participants46 participantsn/r
Liraglutide Liraglutide Placebo, Pre-diabetes128 participants42 participants107 participantsn/r
Liraglutide 3.0 mg622 participants300 participants388 participantsn/r
Liraglutide 3.0 mg138 participants66 participants108 participantsn/r
Liraglutide 1.8 mg66 participants21 participants37 participantsn/r
Liraglutide Placebo29 participants12 participants27 participantsn/r
Liraglutide 3.0 mg101 participants35 participants38 participantsn/r
Liraglutide Placebo36 participants5 participants26 participantsn/r
Liraglutide 3.0 mg58 participants32 participants45 participantsn/r
Liraglutide Placebo23 participants12 participants30 participantsn/r
Liraglutide 3.0 mg47 participants13 participants29 participantsn/r
Liraglutide Placebo12 participants5 participants14 participantsn/r
Liraglutide Semaglutiden/rn/rn/rn/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebo (liraglutide)19 participants5 participants22 participantsn/r
Liraglutide Liraglutiden/rn/rn/rn/r
Liraglutide Placebon/rn/rn/rn/r
Liraglutide 3.0 mg68 participants33 participants31 participantsn/r
Liraglutide Placebo, in trial25 participants7 participants23 participantsn/r
Liraglutide Liraglutide53 participants43 participants28 participantsn/r
Liraglutide Placebo18 participants5 participants18 participantsn/r
Liraglutide Metformin XR plus liraglutide29 participantsn/r14 participantsn/r
Liraglutide Metformin XR plus placebo2 participantsn/r13 participantsn/r
Liraglutide Liraglutide Pen Injector (Saxenda)14 participants5 participants4 participantsn/r
Liraglutide Placebo liraglutide pen injector3 participants0 participants0 participantsn/r
Liraglutide Liraglutide1 participants2 participants10 participantsn/r
Liraglutide Placebo0 participants0 participants2 participantsn/r
Liraglutide 0.05 mg32 participants8 participants20 participantsn/r
Liraglutide 0.1 mg42 participants18 participants25 participantsn/r
Liraglutide 0.2 mg45 participants24 participants35 participantsn/r
Liraglutide 0.3 mg43 participants11 participants27 participantsn/r
Liraglutide 0.4 mg49 participants17 participants38 participantsn/r
Liraglutide 3.0 mg46 participants11 participants29 participantsn/r
Liraglutide Placebo + Metformin12 participants5 participants10 participantsn/r
Liraglutide Liraglutide + Metformin17 participants3 participants4 participantsn/r
Liraglutide 100 mcg23 participants10 participants13 participantsn/r
Liraglutide 200 mcg85 participants51 participants49 participantsn/r
Liraglutide 300 mcg105 participants43 participants28 participantsn/r
Liraglutide 2.4 mg32 participants9 participants18 participantsn/r
Liraglutide 4.5 mg47 participants8 participants7 participantsn/r
Liraglutide 1.2 mg37 participants5 participants8 participantsn/r
Liraglutide 0.6 mg27 participants6 participants10 participantsn/r
Liraglutide 0.3 mg20 participants6 participants15 participantsn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mg39 participants20 participants18 participantsn/r
Liraglutide 3.0 mg29 participants6 participants20 participantsn/r
Liraglutide 3.0 mg35 participants12 participants15 participantsn/r
Liraglutide 3.0 mg34 participants13 participants16 participantsn/r
Liraglutide 3.0 mg47 participants13 participants18 participantsn/r
Liraglutide Orlistat8 participants0 participants33 participantsn/r
Lixisenatide Lixisenatiden/rn/rn/rn/r
Lixisenatide Sitagliptinn/rn/rn/rn/r
Mazdutide 3/6 Milligrams (mg) Mazdutide14 participants7 participants9 participantsn/r
Mazdutide 10 mg22 participants6 participants12 participantsn/r
Mazdutide 16 mg34 participants24 participants13 participantsn/r
Mazdutide Placebo12 participants1 participants6 participantsn/r
Mazdutide 6 mgn/rn/rn/rn/r
Oral Semaglutide Oral semaglutide173 participants80 participants89 participantsn/r
Oral Semaglutide Oral semaglutide placebo51 participants12 participants56 participantsn/r
Oral Semaglutide 25 mg95 participants63 participants36 participantsn/r
Oral Semaglutide Oral semaglutide placebo19 participants6 participants9 participantsn/r
Oral Semaglutide 50 mg34 participants20 participants22 participantsn/r
Oral Semaglutide oral semaglutide placebo once daily5 participants2 participants6 participantsn/r
TERN-601 250 mg16 participants2 participants4 participantsn/r
TERN-601 500 mg17 participants10 participants4 participantsn/r
TERN-601 750 mg20 participants11 participants1 participantsn/r
TERN-601 Matching Placebo3 participants0 participants2 participantsn/r
CT-868 CT-868 Placebo2 participants0 participants2 participantsn/r
CT-868 1.8 mg13 participants4 participants6 participantsn/r
CT-868 4.1 mg17 participants8 participants6 participantsn/r
CT-868 6.6 mg9 participants8 participants6 participantsn/r
HM15211 HM152111 participants1 participantsn/rn/r
HM15211 Placebo1 participants1 participantsn/rn/r
Pramlintide Placebo-P + Placebo-M4 participants0 participants5 participantsn/r
Pramlintide 360 mcg31 participants6 participants5 participantsn/r
Pramlintide 5.0 mg4 participants3 participants3 participantsn/r
Pramlintide 2.5 mg27 participants0 participants5 participantsn/r
Pramlintide 5.0 mg21 participants2 participants4 participantsn/r
Pramlintide 1.25 mg26 participants5 participants4 participantsn/r
Pramlintide 2.5 mg29 participants1 participants7 participantsn/r
Pramlintide 5.0 mg19 participants1 participants3 participantsn/r
Pramlintide 13 participants0 participants1 participantsn/r
Pramlintide 22 participants0 participants2 participantsn/r
Pramlintide 35 participants0 participants1 participantsn/r
Pramlintide Placebo1 participantsn/rn/rn/r
Pramlintide Pramlintide + Metreleptin7 participantsn/rn/rn/r
Pramlintide Pramlintide Acetate and Placebo7 participants2 participants0 participantsn/r
Pramlintide Lead-In Period10 participants3 participants2 participantsn/r
Bimagrumab 30 mg9 participants1 participants10 participantsn/r
Bimagrumab 30 mg15 participants5 participants27 participantsn/r
Bimagrumab 30 mg20 participants7 participants25 participantsn/r
Bimagrumab 1.0 mg25 participants6 participants19 participantsn/r
Bimagrumab 2.4 mg26 participants10 participants21 participantsn/r
Bimagrumab 1.0 mg23 participants6 participants27 participantsn/r
Bimagrumab 2.4 mg34 participants10 participants29 participantsn/r
Naltrexone And Bupropion NB16155 participants36 participants31 participantsn/r
Naltrexone And Bupropion NB32171 participants56 participants26 participantsn/r
Naltrexone And Bupropion Placebo30 participants14 participants28 participantsn/r
Naltrexone And Bupropion NB32290 participants84 participants55 participantsn/r
Naltrexone And Bupropion Placebo34 participants10 participants18 participantsn/r
Naltrexone And Bupropion NB32199 participants64 participants43 participantsn/r
Naltrexone And Bupropion Placebo21 participants13 participants15 participantsn/r
Naltrexone And Bupropion NB32141 participants61 participants52 participantsn/r
Naltrexone And Bupropion Placebo12 participants6 participants16 participantsn/r
Naltrexone And Bupropion BWL + NB medication13 participants1 participants3 participantsn/r
Naltrexone And Bupropion BWL + Placebo5 participants0 participants9 participantsn/r
Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication7 participants2 participants3 participantsn/r
Naltrexone And Bupropion BWL + Placebo0 participants0 participants3 participantsn/r
Naltrexone And Bupropion NB medication8 participants3 participants2 participantsn/r
Naltrexone And Bupropion Placebo3 participants3 participants5 participantsn/r
Naltrexone And Bupropion Naltrexone+Bupropion Medication0 participantsn/rn/rn/r
Naltrexone And Bupropion Placebo1 participantsn/rn/rn/r
Naltrexone And Bupropion Naltrexone/Bupropion0 participants0 participants0 participantsn/r
Naltrexone And Bupropion Placebo0 participants0 participants0 participantsn/r
Orlistat Intensive Lifestyle Mod. Interventionn/rn/r35 participantsn/r
Orlistat Standard Lifestyle Interventionn/rn/r9 participantsn/r
Orlistat Placebo9 participants7 participants8 participantsn/r
Orlistat Orlistat10 participants7 participants21 participantsn/r
Phentermine And Topiramate VI-0521 Low14 participantsn/r12 participantsn/r
Phentermine And Topiramate VI-0521 Top37 participantsn/r24 participantsn/r
Phentermine And Topiramate Placebo24 participantsn/r23 participantsn/r
Phentermine And Topiramate VI-0521 Top8 participantsn/r6 participantsn/r
Phentermine And Topiramate VI-0521 Mid9 participantsn/r4 participantsn/r
Phentermine And Topiramate TPM 468 participantsn/r3 participantsn/r
Phentermine And Topiramate TPM 925 participantsn/r6 participantsn/r
Phentermine And Topiramate PHEN 7.55 participantsn/r1 participantsn/r
Phentermine And Topiramate PHEN 156 participantsn/r4 participantsn/r
Phentermine And Topiramate Placebo5 participantsn/r5 participantsn/r
Phentermine And Topiramate LSMT 120 participantsn/rn/rn/r
Phentermine And Topiramate LSMT 241 participantsn/rn/rn/r
Phentermine And Topiramate Phentermine & Topiramaten/rn/r1 participantsn/r
Phentermine And Topiramate Placebo Drugsn/rn/r3 participantsn/r
Phentermine And Topiramate Semaglutiden/rn/rn/rn/r
Phentermine And Topiramate Other anti-obesity medicationn/rn/rn/rn/r
Setmelanotide Setmelanotide28 participants21 participants17 participantsn/r
Setmelanotide Placebo17 participants14 participants14 participantsn/r
Setmelanotide Setmelanotide49 participants36 participants19 participantsn/r
Setmelanotide Setmelanotide (Double-Blind)7 participants7 participants2 participantsn/r
Setmelanotide Placebo (Double-Blind)6 participants0 participants1 participantsn/r
Setmelanotide Setmelanotide (Open-label)8 participants8 participants7 participantsn/r
Setmelanotide Pivotal Cohortn/rn/rn/rn/r
Setmelanotide 2 mg0 participants0 participants0 participantsn/r
Setmelanotide 2.5 mg0 participants0 participants0 participantsn/r
Setmelanotide 3 mg0 participants0 participants0 participantsn/r
Setmelanotide 20 mg0 participants0 participants0 participantsn/r
Setmelanotide 25 mg1 participants0 participants0 participantsn/r
Setmelanotide 3 mg3 participants2 participants2 participantsn/r
Setmelanotide 30 mg0 participants0 participants0 participantsn/r
Setmelanotide 20 mg0 participants0 participants0 participantsn/r
Setmelanotide 25 mg1 participants0 participants0 participantsn/r
Setmelanotide 30 mg0 participants1 participants2 participantsn/r
Setmelanotide Setmelanotide8 participants2 participants7 participantsn/r
Setmelanotide Setmelanotide8 participants8 participants5 participantsn/r
Setmelanotide Setmelanotide: PPL Groupn/r4 participants2 participantsn/r
Setmelanotide Setmelanotide: BBS Groupn/r3 participants0 participantsn/r
Setmelanotide 16p11.2 Cohort9 participants1 participants1 participantsn/r
Setmelanotide AS Cohort1 participants0 participants0 participantsn/r
Setmelanotide BBS Cohort3 participants2 participants2 participantsn/r
Setmelanotide MC4R Cohort12 participants7 participants7 participantsn/r
Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort14 participants4 participants3 participantsn/r
Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort4 participants2 participants0 participantsn/r
Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort13 participants6 participants1 participantsn/r
Setmelanotide SH2B1 Cohort13 participants6 participants4 participantsn/r
Setmelanotide SMS Cohort2 participants0 participants4 participantsn/r
Setmelanotide SRC1 Cohort11 participants4 participants1 participantsn/r
Setmelanotide Stage 1: Setmelanotide (Open-Label)75 participants41 participants22 participantsn/r
Setmelanotide Stage 2: Setmelanotide (Double-Blind)4 participants3 participants2 participantsn/r
Setmelanotide Stage 2: Placebo (Double-Blind)0 participants0 participants0 participantsn/r
Setmelanotide Placebo0 participants0 participants0 participantsn/r
Setmelanotide Setmelanotide5 participants0 participants1 participantsn/r
Setmelanotide Placebo3 participants2 participants0 participantsn/r
Setmelanotide 0.5 mg0 participantsn/rn/rn/r
Setmelanotide 1.5 mg0 participantsn/rn/rn/r
Setmelanotide 2.5 mg0 participantsn/rn/rn/r
Setmelanotide Placebo1 participantsn/rn/rn/r
Sibutramine Sibutramine0 participants0 participants0 participantsn/r
Sibutramine Placebo5 participants5 participants7 participantsn/r
Tesofensine placebo arm2 participants2 participants2 participantsn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.